Biological Variation of Cardiac Biomarkers in Aortic Valve Stenosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02510482

Enrollment

Registered

2015-07-29

Start date

2015-08-31

Completion date

2017-10-16

Last updated

2017-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Stenosis

Keywords

cardiac biomarkers

Brief summary

Calcified aortic valve stenosis (CAVS) is a progressive disease and nowadays, the cornerstone in diagnostics and follow-up is echocardiography. Cardiac biomarkers (such as cardiac troponins T and I and NT-pro-BNP) hold promise to fulfil a role in early recognition of complications concerning the aortic valve and decompensation. For this purpose, it is important to assess the normal biological variation (BV) of cardiac biomarkers in CAVS. The assessment of biological variation will contribute to a better understanding of fluctuation of cardiac biomarkers in subjects with stable CAVS. These data will improve monitoring of CAVS using cardiac biomarkers.

Interventions

OTHERNo intervention

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinically stable moderate aortic valve stenosis * No evidence of acute cardiovascular disease

Exclusion criteria

* Acute myocardial infarction in the last six months * Pulmonary embolism in the last six months * Hospitalisation for heart failure in the last six months * Chronic kidney disease

Design outcomes

Primary

Measure	Time frame
Cardiac troponin T	One year
Cardiac troponin I	One year
NT-pro-BNP	One year

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026